锕锕锕锕锕锕～再深点+在线观看,痛痛痛痛痛痛疼疼色板推特,天天碰天天爱天天摸,成人18毛片女人

Dr. Xiang S Ye is executive director of Lilly Oncology Discovery China/Asia. Dr. Ye joined Eli Lilly in early 1998. At Lilly, Dr. Ye led discovery research efforts for novel cancer drugs targeting cancer cell cycle and signaling and delivered 8 clinical candidates, including abemaciclib, a CDK4/6 inhibitor, designated as a breakthrough medicine, and approved by FDA in 2017. In 2008, Dr. Ye served as an Enduring Team Leader and led a group of scientists across the drug R&D value chain in a corporate initiative to speed up drug development and had the responsibility in managing a LO to Phase II portfolio. The team delivered 4 clinical candidates, 2 IND and a Phase II milestones. Dr. Ye has published more than 60 scientific papers and book chapters. Dr. Ye was relocated to Shanghai in 2011 to lead Lilly Oncology Discovery China/Asia and delivered the first clinical candidate in early 2014 from China discovery research. In his current role, Dr. Ye also supervised postdoctoral scientists in China, served as corporate supervisor at Shanghai Science and Technology University, and has leadership roles in several pre-competitive consortia programs, and industry and academic collaborations to promote cancer research and drug development in China/Asia.